Gilead Sciences Inc.: PharmaVitae Profile

Published by: Datamonitor

Published: Sep. 16, 2009

Table of Contents

ABOUT DATAMONITOR HEALTHCARE

About the PharmaVitae team

Chapter 1 About this profile

PharmaVitae Explorer database

Chapter structure

Data sourcing

Chapter 2 Executive summary

Key findings

Prescription pharmaceutical sales and growth rate performance, 2002-14

Financial performance, 2002-14

Gilead Sciences: PharmaVitae forecasts at a glance

Strategic insight

SWOT analysis

Chapter 3 Quarterly news update

Product developments

Deals and alliances

M&A activity

Company announcements

Future product milestones

Chapter 4 Company introduction

Key findings

Background

Key corporate developments

M&A history

Chapter 5 Company sales

Key findings

Prescription pharmaceutical sales and growth rate analysis, 2002-14

Product analysis

Therapy area analysis

Geographic analysis

Launch/core/expiry analysis

Molecule type analysis

Externalization analysis

Chapter 6 Company financials

Key findings

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08

Operating costs and profit analysis

Chapter 7 Key products and competitors

Key findings

Overview

Infectious diseases

Cardiovascular

Chapter 8 Appendix

R&D pipeline

References

Abbreviations

About Datamonitor

Datamonitor consulting

Disclaimer

List of Tables

Table 1: Gilead - PharmaVitae forecasts at a glance

Table 2: Gilead’s HIV franchise, 2008-14 ($m)

Table 3: Gilead key product developments, 2009

Table 4: Gilead product deals and alliances, 2009

Table 5: Gilead technology deals and alliances, 2009

Table 6: Gilead M&A activity, 2009

Table 7: Gilead company announcements, 2009

Table 8: Gilead future product milestones, 2009-11

Table 9: Gilead product portfolio overview ($m), 2002-08

Table 10: Gilead product portfolio overview ($m), 2008-14

Table 11: Gilead prescription pharmaceutical sales by therapy area ($m), 2008-14

Table 12: Gilead prescription pharmaceutical sales by geographic region ($m), 2008-14

Table 13: Gilead launch portfolio overview ($m), 2008-14

Table 14: Gilead core portfolio overview ($m), 2008-14

Table 15: Gilead expiry portfolio overview ($m), 2008-14

Table 16: Gilead prescription pharmaceutical sales by molecule type ($m), 2008-14

Table 17: Gilead prescription pharmaceutical sales by source ($m), 2008-14

Table 18: Total Gilead sales by business unit ($m), 2002-08

Table 19: Gilead operating revenue/cost analysis ($m), 2002-08

Table 20: Gilead operating cost ratio analysis (% of total revenues), 2002-08

Table 21: Gilead operating cost ratio analysis (% of total revenues), 2008-14

Table 22: Gilead operating revenue/cost analysis ($m), 2008-14

Table 23: Key products overview

Table 24: Atripla: overview

Table 25: Atripla: sales forecast ($m), 2008-14

Table 26: Truvada: overview

Table 27: Truvada: sales forecast ($m), 2008-14

Table 28: Viread: overview

Table 29: Viread: sales forecast ($m), 2008-14

Table 30: Truvada + rilpivirine: overview

Table 31: Truvada + rilpivirine: sales forecast ($m), 2008-14

Table 32: Letairis: overview

Table 33: Letairis: sales forecast ($m), 2008-14

Table 34: Gilead Sciences R&D pipeline (Phase I-registration)

TABLE OF FIGURES

Figure 1: The PharmaVitae Explorer

Figure 2: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14

Figure 3: Gilead’s financial performance ($m), 2002-14

Figure 4: Sales of the leading HIV therapy players, 2002-14 ($m)

Figure 5: Gilead prescription pharmaceutical sales by source, and therapy area ($m), 2002-14

Figure 6: Gilead SWOT analysis

Figure 7: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14

Figure 8: Key product sales ($m), 2002-14

Figure 9: Gilead key sales growth drivers and resistors ($m), 2002-08

Figure 10: Gilead key sales growth drivers and resistors ($m), 2008-14

Figure 11: Gilead prescription pharmaceutical sales by therapy area ($m), 2002-14

Figure 12: Gilead prescription pharmaceutical sales by geographic region ($m), 2002-14

Figure 13: Gilead launch/core/expiry configuration ($m), 2008-14

Figure 14: Gilead prescription pharmaceutical sales by molecule type ($m), 2002-14

Figure 15: Gilead prescription pharmaceutical sales by source ($m), 2002-14

Figure 16: Gilead operating revenue/cost analysis ($m), 2002-14

Abstract

• Benchmark Gilead's performance against key rivals in the prescription pharmaceutical sector
• See how Gilead's HIV franchise will drive continued double-digit sales growth for the company out to 2014
• Assess the impact of the company's recently announced collaboration with Tibotec for a 'second generation Atripla'

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.